Lupartumab
Lupartumab (BAY 1112623) is an anti-LYPD3 (C4.4A) monoclonal antibody that can be used for the synthesis of antibody-drug conjugate BAY 1129980[1].
Product Specifications
CAS Number
[1640971-88-5]
Product Name Alternative
BAY 1112623
UNSPSC
12352203
Target
ADC Antibody
Type
Inhibitory Antibodies
Related Pathways
Antibody-drug Conjugate/ADC Related
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/lupartumab.html
Purity
99.52
Solubility
H2O
Smiles
[Lupartumab]
Molecular Weight
(145.5 kDa)
References & Citations
[1]Willuda J, et al. Preclinical Antitumor Efficacy of BAY 1129980-a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody-Drug Conjugate for the Treatment of Non-Small Cell Lung Cancer. Mol Cancer Ther. 2017 May;16 (5) :893-904.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 1
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS2076372-01 0.1 mL
APC/CY7-Linked Polyclonal Antibody to C-Terminal Binding Protein 2 (CTBP2)
Ask
View Details 
MBS2076372-02 0.2 mL
APC/CY7-Linked Polyclonal Antibody to C-Terminal Binding Protein 2 (CTBP2)
Ask
View Details MBS2076372-03 0.5 mL
APC/CY7-Linked Polyclonal Antibody to C-Terminal Binding Protein 2 (CTBP2)
Ask
View Details